Sutimlimab
Based on 1 Customer Validation
Sutimlimab is a humanized monoclonal IgG4 antibody. Sutimlimab inhibits complement protein component 1, s subcomponent (C1s). Sutimlimab blocks C3 and C4 activation. Sutimlimab can be used for the research of cold agglutinin disease and complement-mediated hemolytic uremic syndrome.
For research use only. We do not sell to patients.
- Purity: 98.81%
- CAS No.: 2049079-64-1
- Molecular Weight:144.8 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Human IgG4 kappa
Human
C1s
Sutimlimab (30 μg/mL) can significantly protect CD46KO cells from complement-mediated cell death, with a relative 1-hour luminescence recovery rate of 73%[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG4 kappa
ELISA, FACS, Functional assay
-
Immobilized C1s/Complement component C1s Protein, Human can bind Sutimlimab. The EC50 for this effect is 16.31 ng/mL. -
Flow Cytometry analysis of A549 cells labelling C1s (red) with Sutimlimab (anti-C1s) (HY-P99050). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. Then cells were stained with the primary antibody at 1/200 dilution for an hour at 4℃. Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG4 kappa (HY-P99003, blue) was used as the isotype control.
Chemical Information
-
CAS No. 2049079-64-1
-
Appearance Liquid
-
Molecular Weight 144.8 kDa
-
Color Colorless to light yellow
-
SMILES
[Sutimlimab]
-
Synonyms
BIVV009; IPN-009; TNT009
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (257 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Portuguese - PT (252 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Alexander Röth, et al. Sutimlimab in Cold Agglutinin Disease. N Engl J Med. 2021 Apr 8;384(14):1323-1334. [Content Brief]
[2]. Cole MA, et al. Complement Biosensors Identify a Classical Pathway Stimulus in Complement-Mediated Hemolytic Uremic Syndrome. bioRxiv [Preprint]. 2024 Jun 2:2024.05.29.596475. [Content Brief]
[3]. Berentsen S. Sutimlimab for the Treatment of Cold Agglutinin Disease. Hemasphere. 2023 May 2;7(5):e879. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)